IL17A and autoimmune disease: This led us to a hypothesis explaining the paradox of inducing autoimmunity by TNF-blockade in context with IL-17-mediated autoimmune diseases and an explanation why VKHD should be treated with anti-IL-17A/F rather than with anti-TNF-α.